in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance..

the news highlighted another factor in the chinese threat: regardless of the different regulatory framework, many researchers think the data they report is valid...

the report "correctly points out that there really was no playbook for dealing with what was an unprecedented health crisis," san diego mayor kevin faulconer said...